COXIBs In Clinical Practice
ثبت نشده
چکیده
9. Some studies have observed an increase in cardiovascular risk in patients on COXIBs; this has not been conclusively studied in well designed clinical trials. Caution is warranted; further safety studies are planned. Additional comments and/or reviews provided by: Dr. P. Pollock (Rheum), Dr. J. Sibley (Rheum), Dr. L. Worobetz (Gastroent), Dr. J. Richardson (Pharm), Dr. D. Blackburn (Col. of Pharm, U. of S.), Brent Jensen (Pharm) & the RxFiles Advisory Committee. Introduction The risk of adverse effects with NSAIDs has led to a search for safer anti-inflammatories. Thus, agents with highly selective inhibition of cyclooxygenase-2 (COX-2) have been developed in hopes of greater safety. The interpretation of studies measuring relative COX-2 to COX-1 selectivity is subject to much debate due to differences in the various assays used. This paper will limit discussion to celecoxib CELEBREX and rofecoxib VIOXX, which have outcome evidence for decreasing gastrointestinal risk.
منابع مشابه
Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice
BACKGROUND Gastrointestinal harm, known to occur with NSAIDs, is thought to be lower with NSAID and gastroprotective agent, and with inhibitors selective to cyclooxygenase-2 (coxibs) at usual plasma concentrations. We examine competing strategies for available evidence of reduced gastrointestinal bleeding in clinical trials and combine this evidence with evidence from clinical practice on wheth...
متن کاملA Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example
BACKGROUND Data on absolute risks of outcomes and patterns of drug use in cost-effectiveness analyses are often based on randomised clinical trials (RCTs). The objective of this study was to evaluate the external validity of published cost-effectiveness studies by comparing the data used in these studies (typically based on RCTs) to observational data from actual clinical practice. Selective Co...
متن کاملItalian survey on the use of anti-inflammatory drugs in osteoarthritis.
Osteoarthritis (OA) is the most common painful arthritic disease in adults, causes severe disability and worsens the quality of life of the patients. The aim of this survey, carried out on 147 Italian orthopedic doctors who attended an ISIAT (International Symposium Intra Articular Treatment) educational course in Barcelona, was to investigate some aspects of daily clinical practice in the mana...
متن کاملChannelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.
BACKGROUND Although clinical trial results suggest that meloxicam has less gastrointestinal toxicity than most other non-steroidal anti-inflammatory drugs (NSAIDs), in practice it has been associated with a large number of yellow card reports of gastrointestinal complications. AIMS To estimate whether meloxicam and the coxibs, rofecoxib and celecoxib, have been channelled towards high risk pa...
متن کاملTopical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury
Acute pain caused by musculoskeletal disorders is very common and has a significant negative impact on quality-of-life and societal costs. Many types of acute pain have been managed with traditional oral non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors (coxibs). Data from prospective, randomised controlled clinical trials and postmarketing surveillance in...
متن کاملDo COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis.
BACKGROUND Both COX-2 selective inhibitors (coxibs) and nonselective (ns)-NSAIDs elevate blood pressure (BP) and this may contribute to excess cardiovascular (CV) events. A number of recent large-scale randomized clinical trials (RCTs) comparing coxibs (including newer agents, lumiracoxib and etoricoxib) to both ns-NSAIDs and placebo have been reported, permitting an update to earlier BP analys...
متن کامل